We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
LumiraDx Ltd | NASDAQ:LMDX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.016 | 0.014 | 0.0146 | 0 | 01:00:00 |
Findings from the survey revealed a few central themes including the ongoing time and bandwidth stresses felt by most clinicians, the future growth of community testing, and, importantly, an overwhelming focus on patient impact. In addition, the report showed a significant increase in clinicians’ comfort with the accuracy and dependability of POCT when compared to the 2021 report.
Key findings included:
“The last few years have been incredibly challenging for physicians across the country,” commented Pooja Pathak, LumiraDx Chief Product Officer. “This survey allows us to get a pulse on how these changes in healthcare are impacting physicians’ attitudes on diagnostics, the stresses that they are feeling and how they are looking for testing to support them in their patient management. From these results we can see not only a growing comfort with point of care testing, but also a growing need for the unique solutions next-generation POCT provides through rapid and accurate results.”
The nationwide blinded survey, conducted by a third-party, was held online between October 7-14th surveying 200 U.S. general practitioners in private, group practices as well as urgent care.
The full survey results for both the U.S and U.K. reports are available at go.lumiradx.com/clinicians-survey-2022.
About LumiraDxLumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.
The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease.
More information on LumiraDx is available at www.lumiradx.com.
Media Contact: Colleen.McMillen@lumiradx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/366ee774-2af0-42e0-a55a-87741c93e2c9
1 Year LumiraDx Chart |
1 Month LumiraDx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions